Sign in
1540P Ripretinib as ≥4th-line treatment in patients with advanced gastrointestinal stromal tumor: Long-term update from the phase III INVICTUS study
Journal article   Peer reviewed

1540P Ripretinib as ≥4th-line treatment in patients with advanced gastrointestinal stromal tumor: Long-term update from the phase III INVICTUS study

M von Mehren, M.C Heinrich, S George, J.R Zalcberg, S Bauer, H Gelderblom, P Schöffski, C Serrano, R.L Jones, S Attia, …
Annals of oncology, Vol.32, pp.S1120-S1121
2021-09

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
International collaboration
Citation topics
1 Clinical & Life Sciences
1.118 Soft Tissue, Bone & Nerve Cancers
1.118.1520 Gastrointestinal Stromal Tumor
Web Of Science research areas
Oncology
ESI research areas
Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Details